NEW YORK – Basel, Switzerland-based Basilea Pharmaceutica on Monday announced that it has begun a Phase I/II trial evaluating its investigational agent derazantinib as a treatment for patients with advanced gastric cancer whose tumors have FGFR alterations.
The study, dubbed FIDES-03, will assess derazantinib, an inhibitor of FGFR1, FGFR2, and FGFR3, both as a monotherapy and in combination with the PD-L1 inhibitor atezolizumab (Roche's Tecentriq). Basilea will sponsor the study, while Roche will supply atezolizumab.